GH Research PLC
NASDAQ:GHRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GH Research PLC
Pre-Tax Income
GH Research PLC
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Pre-Tax Income
-$48.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-155%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Pre-Tax Income
-$1.3B
|
CAGR 3-Years
-111%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Pre-Tax Income
-$627.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Pre-Tax Income
-$3.3m
|
CAGR 3-Years
69%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
22%
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Pre-Tax Income
-€918k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Pre-Tax Income
-€3k
|
CAGR 3-Years
92%
|
CAGR 5-Years
72%
|
CAGR 10-Years
54%
|
|
GH Research PLC
Glance View
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.
See Also
What is GH Research PLC's Pre-Tax Income?
Pre-Tax Income
-48.3m
USD
Based on the financial report for Dec 31, 2025, GH Research PLC's Pre-Tax Income amounts to -48.3m USD.
What is GH Research PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-155%
Over the last year, the Pre-Tax Income growth was -24%. The average annual Pre-Tax Income growth rates for GH Research PLC have been -29% over the past three years , -155% over the past five years .
